An Unclear Role for the GLP-1 Metabolite GLP-1(9-36) in Human Islet Physiology. Reply to Matveyenko A, Vella A [letter]
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Gandasi N, Gao R, Kothegala L, Pearce A, Santos C, Acreman S
. GLP-1 metabolite GLP-1(9-36) is a systemic inhibitor of mouse and human pancreatic islet glucagon secretion. Diabetologia. 2023; 67(3):528-546.
PMC: 10844371.
DOI: 10.1007/s00125-023-06060-w.
View
2.
Sathananthan M, Farrugia L, Miles J, Piccinini F, Dalla Man C, Zinsmeister A
. Direct effects of exendin-(9,39) and GLP-1-(9,36)amide on insulin action, β-cell function, and glucose metabolism in nondiabetic subjects. Diabetes. 2013; 62(8):2752-6.
PMC: 3717878.
DOI: 10.2337/db13-0140.
View
3.
Haedersdal S, Lund A, Nielsen-Hannerup E, Maagensen H, Forman J, Holst J
. The glucagon receptor antagonist LY2409021 does not affect gastrointestinal-mediated glucose disposal or the incretin effect in individuals with and without type 2 diabetes. Eur J Endocrinol. 2022; 187(4):507-518.
DOI: 10.1530/EJE-22-0291.
View
4.
Haedersdal S, Lund A, Maagensen H, Nielsen-Hannerup E, Gasbjerg L, Rosenkilde M
. The glucagon receptor antagonist LY2409021 has no effect on postprandial glucose in type 2 diabetes. Eur J Endocrinol. 2021; 186(2):207-221.
DOI: 10.1530/EJE-21-0865.
View
5.
Ramracheya R, Chapman C, Chibalina M, Dou H, Miranda C, Gonzalez A
. GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P/Q-type Ca channels. Physiol Rep. 2018; 6(17):e13852.
PMC: 6125244.
DOI: 10.14814/phy2.13852.
View